Tracked deals
13
13 tracked deals across 2021-2026.
Kalamazoo, Michigan, United States
Stryker is a global leader in medical technologies, providing innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes.
Tracked deals
13
13 tracked deals across 2021-2026.
Recent pace
3
3 tracked deals announced in the last 12 months.
Deal mix
Buyout
11 buyout · 1 divestiture · 1 growth capital
Last 6 years
Supporting Data
Showing the 12 most recent of 13 tracked deals for Stryker.
Stryker agreed to invest approximately $400 million in CMR Surgical through preferred equity, with an exclusive option to acquire the company’s remaining equity in the future. The strategic alliance also makes Stryker the exclusive U.S. sales agent for CMR’s Versius portfolio, while CMR retains product development and commercialization outside the United States.
Stryker has signed a definitive agreement to acquire ZuriMED, a privately held medical technology company that developed the FiberLocker System for rotator cuff augmentation. The acquisition is intended to strengthen Stryker’s shoulder portfolio and support specialists across sports medicine and shoulder arthroplasty.
Stryker completed its acquisition of Amplitude Vascular Systems, a privately held medical device company developing a next-generation intravascular lithotripsy (IVL) platform for calcified peripheral arterial disease (PAD). The deal was announced April 13, 2026 and closed May 7, 2026; financial terms were not disclosed in the MedDeviceGuide account, though other sources cite a value of up to $835 million.
Stryker, a medical technologies company, announced a definitive agreement to acquire Inari Medical in an all-cash transaction valued at approximately $4.9 billion ($80 per share). Following the tender offer, the acquisition will be completed via a second-step merger at the same price, with closing anticipated by the end of Q1 2025.
Stryker has completed the acquisition of NICO Corporation, a privately held developer of minimally invasive neurosurgical systems including BrainPath and Myriad. The purchase expands Stryker's neurotechnology portfolio and strengthens its capabilities in tumor resection and treatment of intracerebral hemorrhage (stroke) worldwide.
Stryker has entered into a definitive agreement to acquire Vertos Medical Inc., a privately held company that develops the minimally invasive Mild® procedure for treating lumbar spinal stenosis. The acquisition expands Stryker’s interventional pain management and minimally invasive treatment portfolio and extends its reach into ambulatory surgery centers; the transaction remains subject to customary closing conditions.
Stryker announced a definitive agreement to acquire care.ai, a privately held developer of AI-assisted virtual care workflows, smart room technology and ambient intelligence sensors. The deal is intended to accelerate Stryker’s healthcare IT and connected-device capabilities by integrating care.ai’s platform with Stryker’s Vocera solutions and device portfolio.
Stryker has completed the acquisition of MOLLI Surgical Inc., a privately held developer of wire-free soft tissue localization technology for breast-conserving surgery. The purchase brings MOLLI's MOLLI 2 localization system and small MOLLI Marker into Stryker's breast-cancer surgical portfolio, expanding its capabilities in oncology surgical solutions.
Stryker has signed a definitive agreement to acquire all issued and outstanding shares of Artelon, a privately held developer of soft tissue fixation products for foot & ankle and sports medicine procedures. The deal adds Artelon's synthetic biomaterial technology and product portfolio (with over 60,000 implantations worldwide) to Stryker's foot & ankle and sports medicine offerings and is subject to customary closing conditions.
Stryker has completed the acquisition of Cerus Endovascular Ltd., a privately held, commercial-stage medical device company that developed the Contour Neurovascular System and Neqstent devices for treatment of intracranial aneurysms. The deal expands Stryker’s Neurovascular portfolio and strengthens its aneurysm/hemorrhagic treatment capabilities globally (reported purchase price approximately $530 million).
Onkos Surgical entered into a definitive agreement to acquire the Juvenile Tumour System (JTS) extendible prosthesis from Stryker. The device enables non‑invasive implant lengthening for pediatric bone cancer and limb reconstruction cases, and the acquisition expands Onkos's musculoskeletal oncology product portfolio and clinical capabilities.
Stryker Corporation completed the acquisition of Vocera Communications, Inc., a provider of clinical communication and workflow solutions, with the effective date of the transaction on February 23, 2022. The deal integrates Vocera's digital care-coordination platform and wearable communication devices into Stryker’s medical technology portfolio; the announcement also triggered change-of-control rights for holders of Vocera's convertible notes.
Turn tracked acquisition activity into an outreach-ready buyer list.